CSIMarket


Candel Therapeutics Inc   (CADL)
Other Ticker:  
 
 

CADL's Income from Cont. Operations Growth by Quarter and Year

Candel Therapeutics Inc 's Income from Cont. Operations results by quarter and year




CADL Income from Cont. Operations (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 0.00 0.00 0.00
III Quarter September -16.16 0.00 0.00 0.00
II Quarter June -17.08 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -33.24 - - -



CADL Income from Cont. Operations third quarter 2021 Y/Y Growth Comment
Candel Therapeutics Inc in the third quarter recorded loss from continued operations of $ -16.16 millions.

According to the results reported in the third quarter, Candel Therapeutics Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Candel Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter.




CADL Income from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Candel Therapeutics Inc 's third quarter 2021 Income from Cont. Operations $ -16.16 millions CADL's Income Statement
Candel Therapeutics Inc 's third quarter 2020 Income from Cont. Operations $ 0.00 millions Quarterly CADL's Income Statement
New: More CADL's historic Income from Cont. Operations Growth >>


CADL Income from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Candel Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CADL's III. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Candel Therapeutics Inc in the III. Quarter 2021 revealed loss from continued operations of $ -16.16 millions, some analyst point out, that current results show improvement relative to the -17.08 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Candel Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Candel Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CADL's III. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Candel Therapeutics Inc in the III. Quarter 2021 admitted loss from continued operations of $ -16.16 millions, management point out, that current results are slight up side compare to the -17.08 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry Candel Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Candel Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Candel Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
12 Months Ending
12 Months Ending
Cumulative Income from Cont. Operations 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
In the Sep 30 2021 period, Candel Therapeutics Inc 's cumulative trailing twelve month Income from Cont. Operations remained unchanged compare to the same period a year ago.

Candel Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
In the Sep 30 2021 period, Candel Therapeutics Inc 's cumulative trailing twelve month Income from Cont. Operations remained unchanged compare to the same period a year ago.

Candel Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
CADL's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for CADL's Competitors
Income from Cont. Operations Growth for Candel Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for CADL's Customers

You may also want to know
CADL's Annual Growth Rates CADL's Profitability Ratios CADL's Asset Turnover Ratio CADL's Dividend Growth
CADL's Roe CADL's Valuation Ratios CADL's Financial Strength Ratios CADL's Dividend Payout Ratio
CADL's Roa CADL's Inventory Turnover Ratio CADL's Growth Rates CADL's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2021
Dexcom Inc -1.80%$ -1.801 millions
Owens and Minor Inc -4.24%$ -4.236 millions
United Therapeutics Corporation-4.96%$ -4.965 millions
Amgen Inc -6.78%$ -6.779 millions
Quidel Corporation-7.11%$ -7.111 millions
Eli Lilly And Company-8.13%$ -8.135 millions
Abiomed Inc -8.45%$ -8.455 millions
Universal Health Services Inc -10.13%$ -10.126 millions
U S Physical Therapy Inc-10.40%$ -10.404 millions
Quest Diagnostics Inc-10.83%$ -10.829 millions
Lemaitre Vascular Inc-13.43%$ -13.430 millions
Vyne Therapeutics Inc -13.87%$ -13.875 millions
Semler Scientific inc -14.71%$ -14.714 millions
Laboratory Corporation Of America Holdings-16.47%$ -16.470 millions
Bristol Myers Squibb Co-17.36%$ -17.359 millions
Electromed Inc -17.98%$ -17.984 millions
Nature s Sunshine Products inc -23.87%$ -23.867 millions
Immune Therapeutics Inc -23.97%$ -23.971 millions
Petmed Express Inc-24.52%$ -24.524 millions
Co diagnostics Inc -27.05%$ -27.051 millions
Elite Pharmaceuticals Inc -27.59%$ -27.587 millions
Collegium Pharmaceutical inc -28.71%$ -28.708 millions
Biodelivery Sciences International Inc -28.92%$ -28.925 millions
Stryker Corp-29.47%$ -29.469 millions
Fitlife Brands Inc -31.61%$ -31.611 millions
Hologic Inc-33.29%$ -33.293 millions
Msa Safety Inc-33.33%$ -33.332 millions
Steris Plc-34.32%$ -34.321 millions
Viemed Healthcare Inc -36.20%$ -36.198 millions
Amedisys Inc-37.52%$ -37.516 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AVPT's Profile

Stock Price

AVPT's Financials

Business Description

Fundamentals

Charts & Quotes

AVPT's News

Suppliers

AVPT's Competitors

Customers & Markets

Economic Indicators

AVPT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071